ESC 365 - Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation

EHRA Premium Access

Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation

Session: Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Topic: Antiarrhythmic drugs (Atrial Fibrillation)

Speaker: Doctor I. Vogiatzis (Veria, GR)

Event: EHRA EUROPACE - CARDIOSTIM 2017

Congress Presentation

Add to my library

About the speaker

Doctor Ioannis A Vogiatzis

General Hospital of Veria, Veria (Greece)

0 follower

6 more presentations in this session

Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.

Speaker: Associate Professor M. Farkowski (Warsaw, PL)

Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study

Comparison of local activation time annotation algorithms in high density mapping of regular atrial tachycardias

Speaker: Professor J. De Pooter (Gent, BE)

Higher persistence but lower compliance with direct oral anticoagulants treatment for atrial fibrillation following a personalized therapeutic information: paradoxical results of the MONACO study

Speaker: Professor J. Davy (Montpellier, FR)

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

Speaker: Doctor J. Osca Asensi (Valencia, ES)

Access the full session

Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Speakers: Doctor I. Vogiatzis, Associate Professor M. Farkowski, Professor J. De Pooter, Professor J. Davy, Doctor J. Osca Asensi

About the event

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources